Neodymium:YAG Lasers: An FDA Report

Walter J. Stark, David Worthen, Jack T. Holladay, George Murray

Research output: Contribution to journalArticlepeer-review

127 Scopus citations


Analysis of data from four neodymium:YAG laser manufacturers submitted to the Food and Drug Administration (FDA) on over 17,000 cases indicate the procedure is safe and effective for cutting opaque posterior lens capsules. A successful opening in the pupillary membrane was achieved in 98% of the cases, and vision improved in 84% of the cases. Clinically significant risks include: a rise in intraocular pressure two to four hours after treatment, damage to the intraocular lens, and rupture of the anterior hyaloid face.

Original languageEnglish (US)
Pages (from-to)209-212
Number of pages4
Issue number2
StatePublished - 1985
Externally publishedYes


  • FDA
  • cystoid macular edema
  • glaucoma
  • intraocular lens
  • neodymium:YAG laser
  • posterior capsule opacification

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Neodymium:YAG Lasers: An FDA Report'. Together they form a unique fingerprint.

Cite this